European Medicines Agency Adopts a Positive Opinion on ​Regeneron's (REGN) Libtayo

​Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy Right Now. On October 17, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that the European Medicines Agency adopted a positive opinion for its Libtayo, which treats adults with cutaneous squamous cell carcinoma.

Earlier this month, Libtayo was approved by the FDA to treat patients with cutaneous squamous cell carcinoma who are at high risk of recurrence after surgery and radiation. Management expects the European Commission to announce its final decision on the application in the coming months.

​This positive opinion is supported by results from the treatment’s global Phase 3 C-POST trial, which showed Libtayo reduced the risk of disease recurrence or death by 68% compared to placebo.

​Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company that discovers, develops, and commercializes medicines for serious diseases.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.